This is how Genmab finds M&A targets
Every year, Genmab screens more than 100 molecules that might become M&A targets, but only a fraction of these prove interesting to the group. But just what is the company’s approach? And how does it guard itself against hostile takeover attempts?
BY BENJAMIN WERNER CHRISTENSEN
The battle to be the first company to develop and launch new, innovative drugs is fierce, which is why the majority of companies in the biotech and pharma markets tend to acquire and offload assets from time to time.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab buys clinical assets from French biotech
For abonnenter
This is Genmab’s main focus for 2015
For abonnenter
Danske: Genmab partner might accelerate launch
For abonnenter
